Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines
- 16 February 2012
- journal article
- review article
- Published by Elsevier BV in Vaccine
- Vol. 30 (17), 2715-2727
- https://doi.org/10.1016/j.vaccine.2012.02.015
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Viral tricks to grid-lock the type I interferon systemCurrent Opinion in Microbiology, 2010
- Mumps virus Enders strain is sensitive to interferon (IFN) despite encoding a functional IFN antagonistJournal of General Virology, 2009
- New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: Studies on growth, metabolism and virus propagationVaccine, 2009
- Expanding the Repertoire of Modified Vaccinia Ankara-Based Vaccine Vectors via Genetic Complementation StrategiesPLOS ONE, 2009
- Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Mycobacterium tuberculosis–infected IndividualsAmerican Journal of Respiratory and Critical Care Medicine, 2009
- An avian cell line designed for production of highly attenuated virusesVaccine, 2009
- Simian virus 40 in humansInfectious Agents and Cancer, 2007
- Adenovirus Type 5 Early Region 1B 156R Protein Promotes Cell Transformation Independently of Repression of p53-Stimulated TranscriptionJournal of Virology, 2007
- Differentially Regulated Interferon Response Determines the Outcome of Newcastle Disease Virus Infection in Normal and Tumor Cell LinesJournal of Virology, 2006
- Negative Regulation of the Alpha Interferon-Induced Antiviral Response by the Ras/Raf/MEK PathwayJournal of Virology, 2006